Cullinan Therapeutics, Inc.
CGEMNASDAQHealthcare● Active
$13.28
$-0.23(-1.70%)
Market Cap$816162240
P/E Ratio—
52W High$16.74
52W Low$5.68
Cullinan Therapeutics, Inc. (CGEM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CGEM · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.75
Est. -$0.84 · +10.3%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
CGEM reports quarterly as a NASDAQ-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.81 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.84 | -$0.75 | +10.3% | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 10, 2026 | -$0.80 | -$0.77 | +3.8% | — | $0.01B | — |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.95 | -$0.77 | +18.9% | — | $0.01B | — |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.83 | -$1.07 | -28.9% | — | — | — |
| ▲ Q2 FY2025 | May 8, 2025 | -$0.78 | -$0.74 | +5.1% | — | — | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.75 | -$0.73 | +2.7% | — | — | — |
| ▲ Q4 FY2024 | Nov 7, 2024 | -$0.78 | -$0.69 | +11.5% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.75
EPS Est.
-$0.84
EPS Surpr.
+10.3%
Revenue
—
Q1 FY2026
Mar 10, 2026Beat
EPS Actual
-$0.77
EPS Est.
-$0.80
EPS Surpr.
+3.8%
Revenue
—
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.77
EPS Est.
-$0.95
EPS Surpr.
+18.9%
Revenue
—
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$1.07
EPS Est.
-$0.83
EPS Surpr.
-28.9%
Revenue
—
Q2 FY2025
May 8, 2025Beat
EPS Actual
-$0.74
EPS Est.
-$0.78
EPS Surpr.
+5.1%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.73
EPS Est.
-$0.75
EPS Surpr.
+2.7%
Revenue
—
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
-$0.69
EPS Est.
-$0.78
EPS Surpr.
+11.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.98 | $-0.98 | $-0.98 | 5 |
| Q3 FY2028 | $-0.95 | $-0.95 | $-0.95 | 5 |
| Q2 FY2028 | $-0.92 | $-0.92 | $-0.92 | 6 |
| Q1 FY2028 | $-0.88 | $-0.88 | $-0.88 | 3 |
| Q4 FY2027 | $-0.57 | $-0.57 | $-0.57 | 2 |
| Q3 FY2027 | $-0.86 | $-0.86 | $-0.86 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +10.3% | $14.99 | $14.72 | -1.80% |
| ▲ Q1 FY2026 | Mar 10, 2026 | +3.8% | $15.31 | $14.91 | -2.61% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +18.9% | $7.31 | $7.35 | +0.55% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -28.9% | $7.88 | $7.03 | -10.79% |
| ▲ Q2 FY2025 | May 8, 2025 | +5.1% | $7.70 | $7.77 | +0.91% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +2.7% | $8.45 | $8.61 | +1.89% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +11.5% | $16.48 | $15.58 | -5.46% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -2.7% | $16.54 | $16.38 | -0.97% |
Q2 FY2026-1.80%
Report Date
May 7, 2026
EPS Beat/Miss
+10.3%
Price Before
$14.99
Price After
$14.72
Q1 FY2026-2.61%
Report Date
Mar 10, 2026
EPS Beat/Miss
+3.8%
Price Before
$15.31
Price After
$14.91
Q4 FY2025+0.55%
Report Date
Nov 6, 2025
EPS Beat/Miss
+18.9%
Price Before
$7.31
Price After
$7.35
Q3 FY2025-10.79%
Report Date
Aug 7, 2025
EPS Beat/Miss
-28.9%
Price Before
$7.88
Price After
$7.03
Q2 FY2025+0.91%
Report Date
May 8, 2025
EPS Beat/Miss
+5.1%
Price Before
$7.70
Price After
$7.77
Q1 FY2025+1.89%
Report Date
Feb 27, 2025
EPS Beat/Miss
+2.7%
Price Before
$8.45
Price After
$8.61
Q4 FY2024-5.46%
Report Date
Nov 7, 2024
EPS Beat/Miss
+11.5%
Price Before
$16.48
Price After
$15.58
Q3 FY2024-0.97%
Report Date
Aug 8, 2024
EPS Beat/Miss
-2.7%
Price Before
$16.54
Price After
$16.38
Avg Beat Reaction-1.09%
Avg Miss Reaction-5.88%
Beat Rate6 / 8 quarters
Largest Move-10.79% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CGEM ends December
Cullinan Therapeutics, Inc. (CGEM) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.75 — beating the analyst consensus of $-0.84 by +10.3%. CGEM has beaten EPS estimates for 3 consecutive quarters. The next CGEM earnings date is expected around September 1, 2026.
Each quarter, investors track CGEM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CGEM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CGEM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CGEM earnings · 5 questionsCullinan Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CGEM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CGEM historically reports after market close (AMC).
CGEM earnings datewhen is CGEM earningsCGEM next earnings datewhen does CGEM report earningsCGEM earnings calendar
▸ Source: FMP · Cullinan Therapeutics, Inc. SEC filings · US GAAP · Cullinan Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026